

The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel

Gerd Burmester,¹ Angel Lanás,² Luigi Biasucci,³ Matthias Hermann,⁴ Stefan Lohmander,⁵ Ignazio Olivieri,⁶ Carmelo Scarpignato,⁷ Josef Smolen,⁸ Chris Hawkey,⁹ Adam Bajkowski,¹⁰ Francis Berenbaum,¹¹ Ferdinand Breedveld,¹² Peter Dieleman,¹³ Maxime Dougados,¹⁴ Thomas MacDonald,¹⁵ Emilio Martin Mola,¹⁶ Tony Mets,¹⁷ Nele Van Den Noortgate,¹⁸ Herman Stoevelaar¹⁹

► Additional data (supplementary table and figures) are published online only. To view these files please visit the journal online at (<http://ard.bmj.com>).

For numbered affiliations see end of article.

Correspondence to

Professor Gerd R Burmester, Department of Rheumatology and Clinical Immunology, Charité – University Medicine, Free University and Humboldt University Berlin, Charitéplatz 1 10117, Berlin, Germany; gerd.burmester@charite.de

Accepted 18 July 2010
Published Online First
10 September 2010

ABSTRACT

Introduction Given the safety issues of non-steroidal anti-inflammatory drugs (NSAID) and the robustness of guidelines, making treatment choices in daily clinical practice is increasingly difficult. This study aimed systematically to analyse the opinions of a multidisciplinary European expert panel on the appropriateness of different NSAID, with or without the use of a proton pump inhibitor (PPI), in individual patients with chronic rheumatic disease.

Methods Using the Research and Development/University of California at Los Angeles appropriateness method, the appropriateness of five (non-)selective NSAID with or without a PPI was assessed for 144 hypothetical patient profiles, ie, unique combinations of cardiovascular and gastrointestinal risk factors. Appropriateness statements were calculated for all indications.

Results All options without PPI were considered appropriate in patients with no gastrointestinal/cardiovascular risk factors. Cyclooxygenase-2 selective inhibitors (C2SI) alone and non-selective NSAID plus PPI were preferred for patients with elevated gastrointestinal risk and low cardiovascular risk. Naproxen plus PPI was favoured in patients with high cardiovascular risk. For the combination of high gastrointestinal/ high cardiovascular risk the use of any NSAID was discouraged; if needed, naproxen plus PPI or a C2SI plus PPI could be considered.

Discussion The panel results may support treatment considerations at the level of individual patients, according to their gastrointestinal/cardiovascular risk profile.

Non-steroidal anti-inflammatory drugs (NSAID) belong to the mainstay treatments for chronic rheumatic diseases. Despite similar effectiveness,^{1–4} the currently available NSAID show pronounced differences in their safety profile. Classic NSAID carry a substantial risk of upper and lower gastrointestinal events, varying from mild symptoms to gastroduodenal ulcers and related serious complications.^{5–6} Besides the dosage and frequency of NSAID use, several patient conditions have been identified to increase the risk of upper gastrointestinal complications, including advanced age, a history of gastrointestinal ulcer and concomitant treatment with corticosteroids, aspirin or anticoagulants.⁷ The later introduced cyclooxygenase-2

selective inhibitors (C2SI) exhibit a more favourable gastrointestinal safety profile,⁸ albeit with individual differences. However, serious concerns about their cardiovascular toxicity have led to the market withdrawal of rofecoxib and regulatory warnings (European Medicines Agency) for the others.⁹ Following new reports that the increased cardiovascular risk may also apply to non-selective NSAID, the US Food and Drug Administration issued ‘black box’ safety warnings for the entire NSAID drug class.¹⁰ Consequently, the choice between the various NSAID is dominated by an uneasy application of the ‘least harm principle’, balancing the various potential adverse events. Despite the available recommendations, there are still several ‘historical’ myths that may perpetuate wrong habits and beliefs in clinical practice.¹¹ In addition, guidelines are generally insufficiently detailed to support, at the level of the individual patient, a treatment choice that duly takes into account (combinations of) different cardiovascular and gastrointestinal risk factors. To bridge this gap between science and practice, we conducted a European panel study, combining the evidence from clinical studies with the opinions of experts from various disciplines.

METHODS

The Research and Development/University of California at Los Angeles (RAND/UCLA) appropriateness method^{12–14} was used.

Panel composition

The panel consisted of 18 experts from 10 European countries, representing all relevant disciplines (see appendix 1). Selection of experts was based on their specific expertise in the field of NSAID.

Panel process

The panel first met in January 2008 to set up the initial rating structure, ie, study population, treatment options (distinctive NSAID or NSAID groups) and clinical variables (relevant to the choice of different NSAID), see supplementary table 1, available online only.

Using an electronic rating program, panelists individually assessed the appropriateness of selected therapeutic options for a number of



This paper is freely available online under the BMJ Journals unlocked scheme, see <http://ard.bmj.com/info/unlocked.dtl>

mutually exclusive profiles on a nine-point scale (reference values: 1, inappropriate; 5, uncertain; 9, appropriate). Following the RAND/UCLA definition, a treatment had to be considered appropriate if the expected benefits exceeded the potential negative consequences by a sufficient margin.¹² Financial costs or other potential constraints had to be disregarded. Together with the rating program, the experts received a literature overview of which the scope and boundaries were determined during the first meeting. This (electronic) document was rather an extensive data overview than a comprehensive synthesis of clinical evidence, and reflected the published English-language literature from 1998 to 2008, with a focus on reports with the highest level of evidence.

The results of the first round were discussed during a plenary meeting (June 2008), leading to a revision of the rating structure and refinement of some treatment options and definitions (see box 1). Thereafter a second individual rating round took place, including 144 different patient profiles and 10 treatment options. Based on the median score and the extent of agreement between the panellists, appropriateness statements (appropriate, inappropriate, uncertain) were calculated for all indications, according to common RAND/UCLA rules.¹³ Indications were deemed appropriate if the median panel score was between 7 and 9, and inappropriate if the median was between 1 and 3, both without disagreement between panellists. Disagreement was defined as a situation in which at least six panellists scored in each of the sections 1–3 and 7–9. All indications not falling in the categories ‘appropriate’ and ‘inappropriate’ were labelled ‘uncertain’.

A third panel meeting (November 2008) was organised to discuss the second round results and their applicability in daily clinical practice. The final ratings were embedded in an electronic tool that allows quick reference of the appropriateness statements for any of the patient profiles included.

Statistical analysis

A correlation matrix (using Spearman’s correlation coefficient for ordinal variables) was applied to investigate the agreement between individual ratings, within and across the various specialities included.

RESULTS

Panel results

Of all theoretical indications rated in this study, approximately one-third were deemed inappropriate, largely attributable to classic NSAID without proton pump inhibitors (PPI) (see supplementary figure 1, available online only). The percentage of appropriate indications was highest for naproxen plus PPI, followed by celecoxib alone and ibuprofen/diclofenac plus PPI. The outcomes were uncertain for more than half of the indications, of which approximately a quarter was caused by disagreement (strong opposite opinions), with highest values for naproxen plus PPI and celecoxib with or without PPI. Global figures show considerable variations in ratings over and within all specialties (supplementary figure 2, available online only).

For the patient profile without any unfavourable conditions, all NSAID without PPI (both classic and C2SI) were considered appropriate (supplementary figure 1, available online only). The presence of any gastrointestinal risk factors led to inappropriate outcomes of classic NSAID alone in the majority of cases. In patients with a low cardiovascular risk and a history of no or uncomplicated upper gastrointestinal events, celecoxib alone and classic NSAID plus PPI were generally favoured over the other options (figure 1). The combination of low cardiovascular risk and a history of complicated upper gastrointestinal events lowers the appropriateness of C2SI alone and naproxen plus PPI (uncertain). For patients with high cardiovascular risk, naproxen plus PPI showed the highest percentage of appropriate indications (46%) (figure 1), whereas the other options scored between

Box 1 Overview of treatment options, variables and definitions used in the second rating round

- ▶ Patient population
 - ▶ Patients with a chronic rheumatic disease for whom treatment with a NSAID is considered
- ▶ Treatment options
 - ▶ Ibuprofen, diclofenac, naproxen, celecoxib, etoricoxib, all without or with the addition of a PPI
- ▶ Clinical variables used for the construction of patient profiles
 - ▶ Age (<65 years; ≥65 years)
 - ▶ History of upper gastrointestinal events (none; uncomplicated; complicated)
 - ▶ Uncomplicated: previous uncomplicated oesophageal, gastric or duodenal event (eg, significant symptoms, ulcer discovered by a clinically indicated work-up);
 - ▶ Complicated: previous complicated oesophageal, gastric or duodenal event (bleeding, obstruction or perforation)
 - ▶ Cardiovascular risk (low; high)
 - ▶ 10-Year risk of fatal cardiovascular disease (heart attack, stroke), based on the (country-specific) *HeartScore* of the European Society of Cardiology; low: <10%; high: ≥10%
 - ▶ Use of low-dose aspirin (yes/no; only in patients with high cardiovascular risk)*
 - ▶ Use of anticoagulants or other antiplatelet agents (yes/no)
 - ▶ Anticoagulants: warfarin, acenocoumarol
 - ▶ Antiplatelet agents: other than low-dose aspirin, for example clopidogrel (only in patients with high cardiovascular risk)*
 - ▶ Use of systemic corticosteroids (yes/no)
 - ▶ Treatment pattern (intermittent; continuous)
 - ▶ Intermittent: short-term but repetitive
 - ▶ Continuous: chronic use with standard doses

*It is assumed that patients with low cardiovascular risk do not take low-dose aspirin or other antiplatelet agents.




Figure 2 User interface of the electronic tool. NSAID, non-steroidal anti-inflammatory drug; PPI, proton pump inhibitor.

Given the complexity of data and to avoid the risk of oversimplification, we feel that an electronic tool (see figure 2) may offer the best opportunities as a quick reference guide to the panel results. In the complex and dynamic area of NSAID use, we feel that such an approach will offer the best chances of benefiting from the perspective of both science and practice.

Funding The study was supported by an unrestricted educational grant from Pfizer. The sponsor was not involved in the panel process and preparation of the manuscript.

Competing interests Panel members received honoraria from Pfizer for the rating activities and their participation in the panel meetings. GB has received fees for clinical trials from Pfizer and is a member of advisory boards and speakers bureau of Pfizer Germany and MSD Germany. AL has participated as a member of the steering committee of the CONDOR trial and as a speaker in symposiums sponsored by Pfizer. AL has also been advisor to AstraZeneca. LB has received fees for speeches and consultancy from Pfizer, Siemens diagnostic, Sanofi-Aventis and Merck. LB has also received a grant from Sanofi-Aventis. MH has received speaking fees from Pfizer and Novartis. SL has received honoraria as a member of advisory boards to Abbott, Boehringer, MerckSerono, NicOx, Pfizer, Sanofi-Aventis. IO received consulting fees, speaking fees and/or honoraria from Schering-Plough, Bristol-Myers Squibb, Pfizer-Wyett, Abbott, Merck Pharmaceutical, Novartis, Sanofi-Aventis and Roche. CS is on the speakers bureau of Pfizer, AstraZeneca and SIDEM Pharma. His laboratory has received research grants from Pfizer. JS has received honoraria for advisory board activities from Pfizer and Novartis. HS has received honoraria from Pfizer for advice to the design of the study and data analysis. TMM has received research grants from Novartis, Pfizer, Ipsen & Menarini; principal investigator for Pfizer, Novartis, Ipsen & Menarini; received consulting or speakers fees from Pfizer, Novartis, Kaiser Permanente, Takeda, Recordati, Servier, Menarini, NiCox & AstraZeneca. CJH received research funding and/or honoraria from AstraZeneca, Atlantic Pharmaceuticals, Bayer, Logical Therapeutics, Novartis Pharma, Pfizer and Reckitt Benckiser. FB received speaker honoraria from Abbott Laboratories. TM, PD, FB, EMM, AB, MD, NVDN: none apart from the general statement in the article: "Panel members received honoraria from Pfizer for the rating activities and their participation in the panel meetings."

Provenance and peer review Not commissioned; externally peer reviewed.

Authors affiliations ¹Department of Rheumatology and Clinical Immunology, Charité – University Medicine, Free University and Humboldt University Berlin, Berlin, Germany

²Department of Gastroenterology, University of Zaragoza, Zaragoza, Spain

³Institute of Cardiovascular, Medicine, Catholic University, Rome, Italy

⁴Department of Cardiology, University Hospital Zürich, Zürich, Switzerland

⁵Department of Clinical, Sciences, Lund University, Lund, Sweden

⁶Department of Rheumatology, Ospedale San Carlo, Potenza, Italy

⁷Department of Clinical Sciences, Division of Gastroenterology, University of Parma, Parma, Italy

⁸Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria

⁹Nottingham Digestive Diseases Centre & BRU, University Hospital, Nottingham, UK

¹⁰Bradshaw Medical Centre and Steering Committee representative of the Primary Care Rheumatology Society, Orrell, Wigan, UK

¹¹Department of Rheumatology, University Pierre & Marie Curie Paris VI, Saint-Antoine hospital, AP-HP, Paris, France

¹²Leiden University Medical Centre, Leiden, The Netherlands

¹³Department of General Medicine, University of Antwerp (ELIZA), Wilrijk, Belgium

¹⁴Paris-Descartes University, Medicine Faculty; UPRES EA 4058; AP-HP, Cochin Hospital, Rheumatology B Dept, Paris, France

¹⁵Medicines Monitoring Unit (MEMO), Division of Medical Sciences, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK

¹⁶Department of Rheumatology, Hospital Universitario La Paz, Autonoma University Madrid, Madrid, Spain

¹⁷Department of Gerontology & Geriatrics VUB, University Hospital, Brussels, Belgium

¹⁸Department of Geriatric Medicine, University Hospital Ghent, Ghent, Belgium

¹⁹Centre for Decision Analysis and Support, Ismar Healthcare, Lier, Belgium

REFERENCES

- Hur C, Chan AT, Tramontano AC, *et al*. Coxibs versus combination NSAID and PPI therapy for chronic pain: an exploration of the risks, benefits, and costs. *Ann Pharmacother* 2006;**40**:1052–63.
- Garner SE, Fidan DD, Frankish RR, *et al*. Celecoxib for rheumatoid arthritis. *Cochrane Database Syst Rev* 2002;**4**:CD003831.
- Deeks JJ, Smith LA, Bradley MD. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. *BMJ* 2002;**325**:619–23.
- Richy F, Scarpignato C, Lanas A, *et al*. Efficacy and safety of piroxicam revisited. A global meta-analysis of randomised clinical trials. *Pharmacol Res* 2009;**60**:254–63.
- Laine L. Proton pump inhibitor co-therapy with nonsteroidal anti-inflammatory drugs—nice or necessary? *Rev Gastroenterol Disord* 2004;**4**(Suppl 4):S33–41.
- Schoenfeld P, Kimmey MB, Scheiman J, *et al*. Review article: nonsteroidal anti-inflammatory drug-associated gastrointestinal complications – guidelines for prevention and treatment. *Aliment Pharmacol Ther* 1999;**13**:1273–85.
- Singh G. Gastrointestinal complications of prescription and over-the-counter nonsteroidal anti-inflammatory drugs: a view from the ARAMIS database. *Arthritis, Rheumatism, and Aging Medical Information System. Am J Ther* 2000;**7**:115–21.

8. **Rostom A, Muir K, Dubé C, et al.** Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane collaboration systematic review. *Clin Gastroenterol Hepatol* 2007;**5**:818–28.
9. **European Medicines Agency (EMA).** Public statement, London 2005. EMA/62838/2005. <http://www.emea.europa.eu/pdfs/human/press/pr/6275705en.pdf> (Accessed: July 2010).
10. **US Food and Drug Administration.** FDA news release, April 2005. <http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2005/ucm108427.htm> (Accessed: July 2010).
11. **Hunt RH, Lanas A, Stichtenoeth DO, et al.** Myths and facts in the use of anti-inflammatory drugs. *Ann Med* 2009;**41**:423–37.
12. **Brook RH, Chassin MR, Fink A, et al.** A method for the detailed assessment of the appropriateness of medical technologies. *Int J Technol Assess Health Care* 1986;**2**:53–63.
13. **Fitch K, Bernstein SJ, Aguilar MS, et al.** The RAND/UCLA appropriateness method user's manual. http://www.rand.org/pubs/monograph_reports/MR1269 (Accessed: July 2010).
14. **Shekelle P.** The appropriateness method. *Med Decis Making* 2004;**24**:228–31.
15. **Dubois RW, Melmed GY, Henning JM, et al.** Guidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyclo-oxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapy. *Aliment Pharmacol Ther* 2004;**19**:197–208.
16. **Chan FK, Abraham NS, Scheiman JM, et al.** Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents. *Am J Gastroenterol* 2008;**103**:2908–18.

APPENDIX 1

European expert panel on the appropriate use of NSAID Gerd R Burmester, Rheumatology, Germany; Francis Berenbaum, Rheumatology, France; Ferdinand Breedveld, Rheumatology, The Netherlands; Maxime Dougados, Rheumatology, France; Emilio Martín Mola, Rheumatology, Spain; Ignazio Olivieri, Rheumatology, Italy; Josef Smolen, Rheumatology, Austria; Stefan Lohmander, Orthopaedics, Sweden; Luigi M Biasucci, Cardiology, Italy; Matthias Hermann, Cardiology, Switzerland; Tom MacDonald, Cardiology and Clinical Pharmacology, UK; Chris Hawkey, Gastroenterology, UK; Angel Lanas, Gastroenterology, Spain; Carmelo Scarpignato, Gastroenterology and Clinical Pharmacology, Italy; Adam Bajkowski, Family Medicine, UK; Peter Dieleman, Family Medicine, Belgium; Tony Mets, Geriatrics, Belgium; Nele Van Den Noortgate, Geriatrics, Belgium.